At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARCT Arcturus Therapeutics Ltd.
Post-Market Trading 01-08 19:37:03 EST
18.95
-1.88
-9.03%
盘后20.01
+1.06+5.59%
18:44 EST
High20.94
Low18.71
Vol326.47K
Open20.59
D1 Closing20.83
Amplitude10.71%
Mkt Cap513.31M
Tradable Cap469.98M
Total Shares27.09M
T/O6.29M
T/O Rate1.32%
Tradable Shares24.80M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Arcturus Therapeutics (ARCT) Initiated with a Buy at Piper Sandler
BRIEF-Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.